Extending the time window for thrombolytic therapy-primum non tardare

The Lancet Neurology

Volumn 8, Issue 12, 2009, Pages 1074-1075

  Lyden, Patrick D ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEEDING; BLOOD CLOT LYSIS; FIBRINOLYTIC THERAPY; LETTER; NEUROLOGIC DISEASE; PRIORITY JOURNAL; STROKE;

HUMANS; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; UNITED STATES;

EID: 71849091797     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(09)70274-1     Document Type: Letter

References (14)

1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 333 (1995) 1581-1587
2. Generalized efficacy of t-PA for acute stroke. Stroke 28 (1997) 2119-2125
3. Fagan S.C., Morgenstern L.B., Petitta A., et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. Neurology 50 (1998) 883-890
4. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 28 (1997) 2109-2118
5. Kwiatkowski T.G., Libman R.B., Frankel M., et al., the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. Effects of tissue plasminogen activator for acute ischemic stroke at one year. N Engl J Med 340 (1999) 1781-1787
6. Lyden P.D. Thrombolytic therapy for acute stroke. 2nd edn. (2005), Humana Press, New Jersey, USA
7. Marler J., Tilley B., Lu M., et al. Early stroke treatment associated with better outcome. Neurology 55 (2000) 1649-1655
8. Hacke W., Donnan G., Fieschi C., et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363 (2004) 768-774
9. Wahlgren N., Ahmed N., Davalos A., et al. Thrombolysis with alteplase 3-4·5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 372 (2008) 1303-1309
10. Hacke W., Kaste M., Bluhmki E., et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359 (2008) 1317-1329
11. Bluhmki E., Chamorro A., and Dávalos A. Stroke treatment with alteplase given 3·0-4·5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol (2009) 10.1016/S1474-4422(09)70264-9 published online Oct 21.
12. Yusuf S., Wittes J., Probstfield J., and Tyroler H. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 266 (1991) 93-98
13. Ovbiagele B., Weir C.J., Saver J.L., Muir K.W., and Lees K.R. Effect of smoking status on outcome after acute ischemic stroke. Cerebrovasc Dis 21 (2006) 260-265
14. Lyden P. Thrombolytic therapy for acute stroke-not a moment to lose. N Engl J Med 359 (2008) 1393-1395